CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA

Launched by ASTRAZENECA · Apr 14, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to study a medication called Capivasertib, which is used to treat breast cancer. The main goal of the study is to check how safe Capivasertib is, discover any side effects that haven't been noticed before, and see how well it works when doctors prescribe it in everyday medical practice in Korea. The trial is not yet recruiting participants, but it will include people of all ages who have been treated with Capivasertib according to the approved guidelines in South Korea.

To participate in the trial, patients must be eligible for the medication and give their written consent to join the study. However, those who are currently part of another clinical trial or are using the medication for reasons outside of its approved use will not be able to join. If you participate, you can expect to be monitored for any side effects and to provide information on your experience with the medication. This study is important for ensuring that Capivasertib is safe and effective for patients in real-life situations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients eligible for and treated with the study drug according to the approved label in South Korea
• • Patients who provide signed and dated written informed consent, either personally or through a legally acceptable representative.
• Exclusion Criteria:
• • Participation in any interventional trial during the treatment of the study drug
• • Other off-label indications according to the approved label in South Korea